PMID- 29668601
OWN - NLM
STAT- MEDLINE
DCOM- 20180424
LR  - 20210109
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 97
IP  - 16
DP  - 2018 Apr
TI  - Efficacy and safety of once-weekly semaglutide for the treatment of type 2 
      diabetes: Protocol for a systematic review and meta-analysis.
PG  - e0420
LID - 10.1097/MD.0000000000010420 [doi]
LID - e0420
AB  - BACKGROUND: It is a great challenge for type 2 diabetes mellitus (T2DM) patients 
      to maintain optimal glycemia, control body weight, blood pressure, and avoiding 
      hypoglycemia. Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1 RAs) can 
      stimulate glucose-dependent insulin while inhibit glucagon secretion, delay 
      gastric emptying, reduce appetite, and energy intake. Recently, a new once-weekly 
      GLP-1 RAs, semaglutide, has been registered to treat patients with T2DM. METHODS: 
      We will search Medline, Embase, Cochrane Library, and the ClinicalTrials.gov 
      Website up to February 2018. Studies will be screened by title, abstract, and 
      full text independently in duplicate. Phase III randomized controlled trials 
      (RCTs) reports efficacy and safety data of semaglutide will be eligible for 
      inclusion. Outcome variables will be assessed included glycemic control indexes 
      (glycosylated hemoglobin [HbA1c]%, fasting plasma glucose [FPG], self-monitoring 
      of blood glucose [SMPG], postprandial self-monitoring of blood glucose [PSMPG]), 
      blood pressure indexes (systolic blood pressure [SBP], diastolic blood pressure 
      [DBP], and pulse rate), body weight control indexes (body weight, body mass index 
      [BMI], and waist circumference), and any adverse events (including adverse events 
      [AEs] varying degrees and AEs occurring in >/=5% patients by preferred term or 
      other of clinical interest). Assessment of risk of bias and data synthesis will 
      be performed using STATA software (version 12, Statacorp, College Station, 
      Texas). Outcomes will report by weight mean difference (WMD) and risk ratios 
      (RRs) and their 95% confidence intervals (95% CIs). Heterogeneity among studies 
      will be evaluated using the I statistic. RESULTS: This review will evaluate 
      glycemic, blood pressure, body weight control, and any adverse events of 
      semaglutide as compared with other therapies. CONCLUSION: Our study will provide 
      a comprehensive picture of semaglutide in T2DM.
FAU - Shi, Fang-Hong
AU  - Shi FH
AD  - Department of Pharmacy, Renji Hospital Department of Pharmacy, Shanghai 
      Children's Medical Center, School of Medicine, Shanghai Jiaotong University, 
      Shanghai, China.
FAU - Li, Hao
AU  - Li H
FAU - Cui, Min
AU  - Cui M
FAU - Zhang, Zai-Li
AU  - Zhang ZL
FAU - Gu, Zhi-Chun
AU  - Gu ZC
FAU - Liu, Xiao-Yan
AU  - Liu XY
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Blood Glucose)
RN  - 0 (Hypoglycemic Agents)
RN  - 53AXN4NNHX (semaglutide)
RN  - 62340-29-8 (Glucagon-Like Peptides)
SB  - IM
MH  - Blood Glucose/metabolism
MH  - Body Weight
MH  - Diabetes Mellitus, Type 2/blood/*drug therapy
MH  - Drug Administration Schedule
MH  - Glucagon-Like Peptides/*administration & dosage/adverse effects
MH  - Humans
MH  - Hypoglycemic Agents/*administration & dosage/adverse effects
MH  - Middle Aged
MH  - Systematic Reviews as Topic
PMC - PMC5916683
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2018/04/19 06:00
MHDA- 2018/04/25 06:00
PMCR- 2018/04/20
CRDT- 2018/04/19 06:00
PHST- 2018/04/19 06:00 [entrez]
PHST- 2018/04/19 06:00 [pubmed]
PHST- 2018/04/25 06:00 [medline]
PHST- 2018/04/20 00:00 [pmc-release]
AID - 00005792-201804200-00027 [pii]
AID - MD-D-18-01647 [pii]
AID - 10.1097/MD.0000000000010420 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2018 Apr;97(16):e0420. doi: 10.1097/MD.0000000000010420.